|
|
News Breaks | | | | March 4, 2013 | | 08:52 EDT |  | DVAX | Dynavax shares should be bought especially on weakness, says Jefferies
After Dynavax received a complete response letter on its Heplisav drug from the FDA, Jefferies believes that a refiling for Heplisav in a restricted population could occur by year-end 2013. The firm maintains a Buy rating on the shares. | |
|
News For DVAX From The Last 14 Days Check below for free stories on DVAX the last two weeks. |
|
|
| There are no results for DVAX |
|
|
|
|
|
|
